Triple-Threat immune attack tested for Tough-to-Treat skin cancer

This study is testing a combination of three immunotherapy drugs for patients with advanced Merkel cell carcinoma, a rare and aggressive skin cancer, that has spread and stopped responding to a common first-line immunotherapy. The goal is to see if adding two new immune-boosting drugs can re-activate the body's immune system to attack the cancer. The treatment involves periodic intravenous infusions and is for patients whose cancer grew despite prior anti-PD-(L)1 therapy.